Si Chuan Shu Zhong Zhi Yao You Xian Gong Si

Main purpose: Diclofenac sodium sustained-release tablets (specification: 0.1g) of Sichuan Yike Pharmaceutical Co., Ltd. were used as the test preparation, and diclofenac sodium sustained-release tablets (trade name: VOLTAREN®, specification: 100mg) certified by Novartis Pharma GmbH were used as the reference preparation. According to the relevant provisions of the bioequivalence test, the bioequivalence of the two preparations in healthy humans was investigated. Secondary purpose: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Main purpose: This study uses the empagliflozin tablets (specification: 25 mg) certified by Sichuan Yike Pharmaceutical Co., Ltd. as the test preparation and the empagliflozin tablets (trade name: Jardiance®, specification: 25 mg) certified by Boehringer Ingelheim International GmbH as the reference preparation to conduct a human bioequivalence test under fasting/postprandial conditions to evaluate the bioequivalence of the test preparation and the reference preparation in healthy subjects. Secondary purpose: Observe the safety of the test preparation and the reference preparation in healthy subjects.

To observe the in vivo kinetics of nifedipine after a single oral administration of nifedipine sustained-release tablets (II) in healthy Chinese subjects, estimate the corresponding pharmacokinetic parameters, and evaluate the bioequivalence of nifedipine sustained-release tablets (II) (Adalat retard) certified by Bayer Hispania, S.L. as the reference preparation. Secondary objective: To observe the safety of nifedipine sustained-release tablets (II) (test preparation) and nifedipine sustained-release tablets (II) (reference preparation) in healthy humans.